文献速递血液淋巴病理

基于全切片图像分析CD3+肿瘤浸润淋巴细胞的免疫评分在弥漫性大B细胞淋巴瘤中的预后影响

Prognostic Impact of the Immunoscore Based on Whole-Slide Image Analysis of CD3+ Tumor-Infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma.
PubMed 文献 · Mod Pathol · 2023-05-29

本研究在104例接受R-CHOP治疗的弥漫性大B细胞淋巴瘤患者中,利用全切片图像分析CD3+ T细胞密度构建免疫评分,发现低CD3+细胞密度与不良总生存和无进展生存相关,且独立于MYC/BCL2双表达等预后因素,并在两个公共数据集中得到验证。

要点

  • 基于全切片图像的CD3+ T细胞密度免疫评分可预测DLBCL患者生存。
  • 低CD3+细胞密度是不良预后因素,独立于双表达状态等参数。
  • 三种量化方法一致性高,均可用于评估CD3+细胞密度。

核心结论

  • 基于全切片图像分析CD3+ T细胞浸润的免疫评分足以预测DLBCL患者的生存。
  • 低CD3+细胞密度是不良预后因素,独立于其他预后参数和双表达状态。

研究设计与样本

  • 回顾性评估104例接受R-CHOP治疗的DLBCL患者。
  • 使用Aperio ImageScope软件分析数字化全切片图像,量化肿瘤区域CD3+细胞密度。
  • 采用三种方法量化CD3+细胞密度:每mm² CD3+细胞数、CD3+细胞与总细胞比值、CD3+细胞与CD20+细胞比值。
  • 使用两个公开数据集进行验证。

主要发现

  • 三种量化方法间高度一致。
  • 低CD3+细胞密度患者血清乳酸脱氢酶水平升高且Ki-67增殖指数高(均P < .05)。
  • 按所有三种方法,低CD3+细胞密度患者总生存和无进展生存均更差(均P < .05)。
  • 低CD3+细胞密度患者总生存差,独立于MYC/BCL2双表达状态、ECOG体能状态或Ann Arbor分期(均P < .05)。
  • 验证队列中,低CD3E mRNA表达患者血清乳酸脱氢酶升高、结外侵犯和双表达状态(P < .05),无进展生存更差(P = .067和P = .002),总生存更差(均P < .05)。

临床怎么用

  • 基于全切片图像的CD3+ T细胞密度免疫评分可用于DLBCL患者预后分层。
  • 低CD3+细胞密度提示不良预后,即使双表达状态等其他因素阴性。

局限性

  • 验证队列中无进展生存的P值之一为P = .067,未达到常规统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An Immunoscore based on tumor-infiltrating T-cell density was validated as a prognostic factor in patients with solid tumors. However, the potential utility of the Immunoscore in predicting the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) is unclear. Here, the prognostic value of an Immunoscore based on tumor-infiltrating CD3+ T-cell density was evaluated in 104 patients with DLBCL who underwent R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy. Digitally scanned whole-slide images were analyzed using Aperio ImageScope software. CD3+ cell densities in the whole tumor area were quantitated using 3 different methods, including number of CD3+ cells/area (mm2), ratio of CD3+ cells to total cells, and ratio of CD3+ cells to CD20+ cells. There was a high concordance among the 3 methods. Patients with low CD3+ cell density had an elevated serum lactate dehydrogenase level and a high Ki-67 proliferation index (all, P < .05). Patients with low CD3+ cell density, according to all 3 methods, had worse overall survival (OS) and worse progression-free survival (P < .05, all). They also had poor OS, independent of MYC/BCL2 double expression (DE) status, Eastern Cooperative Oncology Group performance status, or Ann Arbor stage (all, P < .05). These results were validated using 2 publicly available data sets. In both validation cohorts, patients with low CD3E mRNA expression had an elevated serum lactate dehydrogenase level, extranodal site involvement, and DE status (P < .05). They also had worse progression-free survival (P = .067 and P = .002, respectively) and OS (both P < .05). A low CD3E mRNA level was predictive of poor OS, independent of DE status. An Immunoscore based on whole-slide image analysis of CD3+ T-cell infiltration was sufficient to predict survival in patients with DLBCL. Low CD3+ cell density was a poor prognostic factor, independent of other prognostic parameters and DE status.

来源:Mod Pathol,查看原文。版权归原作者所有。

引用

  1. Han B, Yim J, Lim S, et al. Prognostic Impact of the Immunoscore Based on Whole-Slide Image Analysis of CD3+ Tumor-Infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma. Mod Pathol. 2023. PMID: 37257823. doi:10.1016/j.modpat.2023.100224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。